Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2026 03:15 ET | Source: Oxford BioTherapeutics

Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3

First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches...
June 18, 2026 08:45 ET | Source: International Myeloma Foundation

International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress

STOCKHOLM, June 18, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI)...
June 10, 2026 10:13 ET | Source: Fight Colorectal Cancer

Climb for a Cure Goes Nationwide: Fight CRC Invites Supporters Across the Country to Join the July 18 Climb From Anywhere

Springfield, Mo., June 10, 2026 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC) is launching a nationwide call to action: recruit 500 climbers in 30 days for its signature Climb for a Cure...
May 28, 2026 10:33 ET | Source: Fortis Life Sciences

Fortis Life Sciences Expands AbNano® Portfolio with First VHH Library Derived from Peripheral Natural Killer Cells for Rapid Antibody Discovery

Fortis Life Sciences launches AbNano® VHH Anti-NK Cell Library, the first NK-cell-derived single-domain antibody library for rapid discovery.
May 28, 2026 09:00 ET | Source: American Oncology Network

American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting

American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting
May 26, 2026 08:00 ET | Source: Artios Pharma

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
May 22, 2026 03:45 ET | Source: Boehringer Ingelheim Limited

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...
May 12, 2026 08:40 ET | Source: Fortis Life Sciences

Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research

Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research
May 12, 2026 08:00 ET | Source: Artios Pharma

Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors

CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response...
May 08, 2026 20:24 ET | Source: Crosetto Foundation for the Reduction of Cancer Deaths

Open Peer-Review Exposes UPV Ethics Committee’s Dilemma: Suppress a 33 Year Recognized Breakthrough or Acknowledge Reviewer’s Ethical Violations and Remit Final Judgement to the Known Dataset Test to Save Millions of Lives and Billions of Euros

Peer-Review Under Fire: reviewers officially forbid authors from comparing technologies, violating fundamental scientific transparency rules.